Trials / Unknown
UnknownNCT05094765
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
Evaluating Safety and Efficacy of GI-XBI-302 in Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Shenzhen Xbiome Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine whether the fecal microbiota transplant (FMT) capsule improves the response rate of GI-aGVHD in patients with glucocorticoid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FMT | Fecal Microbiota Transplantation |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-03-02
- Completion
- 2023-03-02
- First posted
- 2021-10-26
- Last updated
- 2021-10-26
Source: ClinicalTrials.gov record NCT05094765. Inclusion in this directory is not an endorsement.